Dr. Sandrine Niyongere, MD

Dr. Niyongere practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Niyongere's NPI, 1386908119, was assigned on June 26, 2012. Dr. Niyongere holds Maryland license D0085404.

Dr. Niyongere's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Niyongere's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. The medical group on file is University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Niyongere practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Niyongere's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Niyongere's licenses on file in 2 states: Maryland and Illinois.

CMS data shows 517 Medicare services from Dr. Niyongere across 7 procedure codes in 2024, for 139 Medicare patients. Medicare paid $40,783 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 139 Medicare patients who saw Dr. Niyongere in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 33% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Niyongere's median patient age at 65, with 54% women.

In 2024, Dr. Niyongere wrote 557 Medicare Part D claims for 52 patients. 72% of them were for generic drugs. CMS names the drug for 383 of them, across 19 drugs with 11 or more claims each, at $1,044,317 in total drug cost. In 2023, CMS named 267 claims across 13 drugs.

Dr. Niyongere accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Niyongere as offering telehealth.

Dmand AI links 22 papers to Dr. Niyongere, published from 2014 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Leukemia, Myelomonocytic, Chronic. Dr. Niyongere has published most often in Leukemia. Dr. Niyongere's most frequent co-authors are Ashkan Emadi, MD, PhD, Vu H. Duong, MD and Maria R. Baer, MD.

Dmand AI links Dr. Niyongere to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute and Leukemia, Myeloid.

CMS Open Payments shows 19 general payments to Dr. Niyongere from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 68% of the total. Eli Lilly and Company paid the most, $1,925.